慢性肺源性心脏病急性加重期患者VEGF和ET-1水平测定及其意义  

Clinical Significance of VEGF and ET-1 Level in Acute Aggravation Phase of Chronic Pulmonary Heart Disease

作　　者：张鸣华[1] 胡永启[1] 赵仁国[1] 林海[1] 龚峰[1] 

机构地区：[1]温州医学院附属第三医院呼吸内科,325200

出　　处：《浙江医学》2004年第8期574-575,共2页Zhejiang Medical Journal

摘　　要：目的探讨慢性肺源性心脏病(简称肺心病)急性加重期患者血浆血管内皮生长因子(VEGF)和血清内皮素(ET-1)检测的临床意义。方法肺心病组68例,为急性加重期患者;正常对照组41例。测定肺心病患者血浆VEGF、ET-1和肺动脉压与动脉血氧分压(PaO2)。结果肺心病组患者血浆VEGF与ET-1水平均高于正常对照组(均P<0.001),且均与肺动脉压水平呈正相关(r=0.72、0.56,均P<0.001),与PaO2水平呈负相关(r=-0.61、-0.53,均P<0.001)。结论血浆VEGF和ET-1可作为肺心病急性加重期判断病情轻重与评价疗效的重要指标之一,值得临床推广应用。Objective To investigate the clinical significance of plasma vascular endothelium growth factor (VEGF) and serum endotheliolysin (ET-1) in acute aggravation phase of chronic pulmonary heart disease. Methods 68 cases of pulmonary heart disease were studied in the research, compared with 41 cases in the control group. Plasma VEGF, ET-1, pulmonary arterial pressure and arterial blood oxygen saturation (PaO2) were measured. Results Plasma VEGF and ET-1 level in chronic pulmonary heart disease group are both higher than in control group (P<0.001), and both have positive correlation with pulmonary arterial pressure (r=0.72, r=0.56, P<0.001) and negative correlation with PaO2(r=-0.61, -0.53, P<0.001). Conclusion Plasma VEGF and ET-1 are both important index to judge of acute aggravation phase of chronic pulmonary heart disease and evaluate the curative effect, which should be generalized in clinical practice.

关 键 词：慢性肺源性心脏病 急性加重期 VEGF ET-1 测定 血管内皮生长因子 内皮素 

分 类 号：R541.5[医药卫生—心血管疾病]